| Over a week ago | ||||
Canaccord analyst Tania… Canaccord analyst Tania Gonsalves lowered the firm's price target on Knight Therapeutics to C$6.75 from C$7 and keeps a Buy rating on the shares. | ||||
Knight Therapeutics and… Knight Therapeutics and Helsinn Healthcare announced that Knight, through one of its wholly-owned subsidiaries, and Helsinn have entered into an exclusive license, distribution and supply agreement for AKYNZEO oral/IV in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI oral/IV in Canada. According to IQVIA, sales of AKYNZEO in Canada and Brazil were approximately $7M in 2021. Under the terms of the agreement, Knight shall have the exclusive right to distribute, promote, market and sell the Products in the licensed territories. Knight will begin commercial activities following a transition period from Helsinn's current licensees. "We are very excited to enter into this agreement with Helsinn for AKYNZEO in Canada, Brazil and other selected Latin American countries, and ALOXI in Canada," said Samira Sakhia, President and CEO of Knight. "These products are highly synergistic with our oncology portfolio and commercial footprint, and we look forward to widening access to these therapies in our target markets. AKYNZEO and ALOXI are leading, guideline-recommended antiemetics that help to prevent one of the most common side effects of chemotherapy." | ||||
Reports Q1 revenue… Reports Q1 revenue C$63.807M vs C$46.069M last year. "I am excited to report that in the first quarter of 2022 Knight's revenues increased by $17,738 or 39%. In addition to the acquisition of Exelon(R), we had revenue growth across all our therapeutic areas driven by market penetration of our key promoted brands and an increase in patient treatments due to reduced COVID-19 restrictions. On the business development front, we entered into an exclusive license, distribution and supply agreements with Helsinn in our key territories", said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc. "As we look to the balance of 2022, we will continue to execute on revenue and EBITDA growth as well as adding new products through business development." | ||||
| Over a month ago | ||||
Canaccord analyst Tania… Canaccord analyst Tania Gonsalves lowered the firm's price target on Knight Therapeutics to C$7 from C$8 and keeps a Buy rating on the shares. | ||||
Raymond James analyst… Raymond James analyst David Novak lowered the firm's price target on Knight Therapeutics to C$7.50 from C$8.50 and keeps an Outperform rating on the shares. | ||||
Stifel analyst Justin… Stifel analyst Justin Keywood downgraded Knight Therapeutics to Hold from Buy with a price target of C$5.30, down from C$7, after the company reported Q4 results that he says showed improvement year-over-year but still missed estimates. The business has improved "substantially" over the last twelve months, but these results and the company's guidance imply limited valuation upside and he also sees seasonal weakness for the upcoming Q1, Keywood tells investors. | |
The guidance is based on… The guidance is based on a number of assumptions, including but not limited to the following: no revenues for business development transactions not completed as of December 31, 2021; discontinuation of certain distribution agreements; Exelon marketing authorization transfer to Knight in June 2022 in Brazil; no interruptions in supply whether due to global supply chain disruptions or general manufacturing issues; no new generic entrants on our key pharmaceutical brands; no unforeseen changes to government mandated pricing regulations; successful commercial execution on product listing arrangements with HMOs, insurers, key accounts, and public payers; successful execution and uptake of newly launched products; no significant restrictions or economic shut down due to the COVID-19 pandemic; foreign currency exchange rates remaining within forecasted ranges. | |
Reports Q4 revenue… Reports Q4 revenue C$58.27M vs. C$55.19M last year. "I am excited to announce that 2021 was a record-setting year in Knight's history, despite the ongoing challenges posed by the pandemic. During the year, we made significant strides towards completing the integration of the Grupo Biotoscana acquisition, all while strengthening the team and processes and driving strong performance. As part of our integration activities, we completed the implementation of several key systems including, a global CRM, HR IS and a global pharmacovigilance system. In addition, we implemented ERP for 14 legal entities in 6 countries. We further strengthened Knight's management team with the addition of a Global VP Commercial, a Global VP Scientific Affairs, a Global VP Legal and Compliance and a Global VP Human Resources and most recently added a VP Manufacturing and Operations, to continue delivering on growth and operational excellence. Our business development team closed the acquisition of Exelon and entered into an exclusive supply and distribution agreement with Incyte. Our regulatory team advanced our portfolio with the approval of Halaven, Lenvima and Rembre in Colombia as well as the approval of Nerlynx, while our commercial team continued to deliver on strong growth of our key brands. It is thanks to the hard work of our employees that we achieved unprecedented results in 2021 and we are entering 2022 with a stronger platform that is well equipped to continue delivering on further growth and success." said Samira Sakhia, President and CEO. |
| Over a quarter ago | ||||
Knight Therapeutics… Knight Therapeutics announced that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Halaven injection. Halaven injection is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer which has continued to spread after at least two previous treatment for advanced cancer. Halaven injection has shown to significantly improve overall survival in patients with advanced or metastatic breast cancer after anthracycline and taxane treatment. Halaven injection indicated extended overall survival of 2.5 months when compared to selected, major existing therapies. Also, Halaven injection demonstrated a statistically significant extension in overall survival over the comparator treatment dacarbazine in patients with locally advanced/recurrent or metastatic soft tissue sarcoma who had disease progression following standard therapies 2. | ||||
Knight Therapeutics… Knight Therapeutics announced that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Lenvima, the orally available multiple receptor tyrosine kinase inhibitor developed by Eisai, for the treatment of radioiodine refractory differentiated thyroid cancer and unresectable hepatocellular carcinoma. Lenvima demonstrated a statistically significant progression-free survival prolongation and response rate in patients with progressive, differentiated thyroid cancer who had become refractory to radioactive iodine therapy. In a separate study in patients with previously untreated unresectable HCC2, Lenvima was proven to be non inferior to sorafenib for overall survival. In addition, Lenvima was statistically significantly superior to sorafenib for progression-free survival and objective response rate. In 2020, there were approximately 5,3043 new patients with thyroid cancer and 2,2893 new patients with liver cancer in Colombia. | ||||
